This page shows the latest OncoVex news and features for those working in and with pharma, biotech and healthcare.
The most advanced is Amgen's OncoVex (talimogene laherparepvec), which in 2013 became the first oncolytic virus to show efficacy in a phase III trial involving people with the skin cancer
OncoVex demonstrates durable response in skin cancer patients. A novel therapy for skin cancer which makes use of the cell-killing activity of a virus has shown efficacy in a phase ... The melanoma immunotherapeutic - talimogene laherparepvec (also known
nilotinib. In development. Vaccines. OncoVEX GM-CSF. In development. Vaccines. MAGE-A3 ASCI.
BioVex's portfolio includes OncoVex (GM-CSF) – an investigational vaccine to treat melanoma and head and neck cancer. ... Philip Astley-Sparke, CEO, BioVex, also praised the agreement: "Amgen is ideally positioned to leverage the potential of OncoVEX
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...